Literature DB >> 2386384

Serum immunoglobulins to endotoxin core glycolipid: acute leukaemia and other cancers.

S K Jackson1, J Parton, G Shortland, J M Stark, E N Thompson.   

Abstract

Circulating antibody to endotoxin core glycolipid and total serum immunoglobulin concentrations were measured in 86 children with cancer (54 with acute lymphoblastic leukaemia, four with acute myeloid leukaemia, and 28 with various solid tumours). Measurements were made before treatment in the group with acute lymphoblastic leukaemia as well as when patients were both on and off chemotherapy. In the other two groups measurements were made when patients were both on and off treatment. Significant reductions in endotoxin antibody and serum immunoglobulin concentrations were found only in patients with acute lymphoblastic leukaemia. In addition, there was a significant correlation between febrile episodes and the concentration of antibody to core glycolipid in the children with acute lymphoblastic leukaemia. These findings suggest that the use of prophylactic high titre endotoxin antibody may be of benefit to children with life threatening Gram negative infections who are receiving cytotoxic chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2386384      PMCID: PMC1792462          DOI: 10.1136/adc.65.7.771

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  16 in total

1.  Bacteremia and fungemia complicating neoplastic disease. A study of 364 cases.

Authors:  C Singer; M H Kaplan; D Armstrong
Journal:  Am J Med       Date:  1977-05       Impact factor: 4.965

2.  Prevention of fever and gram negative infection after open heart surgery by antiendotoxin.

Authors:  R Freeman; F K Gould
Journal:  Thorax       Date:  1985-11       Impact factor: 9.139

3.  Infection during remission induction in childhood leukaemia.

Authors:  J M Chessells; A D Leiper
Journal:  Arch Dis Child       Date:  1980-02       Impact factor: 3.791

4.  Neutropenia, fever, and infection.

Authors:  A E Brown
Journal:  Am J Med       Date:  1984-03       Impact factor: 4.965

5.  Anti-lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynaecological origin.

Authors:  E Lachman; S B Pitsoe; S L Gaffin
Journal:  Lancet       Date:  1984-05-05       Impact factor: 79.321

6.  Immunosuppressive consequences of radiotherapy and chemotherapy in patients with acute lymphoblastic leukaemia.

Authors:  A C Campbell; P Hersey; I C MacLennan; H E Kay; M C Pike
Journal:  Br Med J       Date:  1973-05-19

7.  Septicemia in childhood malignancy. Analysis of 101 consecutive episodes.

Authors:  J S Miser; A W Miser; W A Bleyer; R L Chard
Journal:  Clin Pediatr (Phila)       Date:  1981-05       Impact factor: 1.168

8.  Age-related prevalence of human serum IgG and IgM antibody to the core glycolipid of Escherichia coli strain J5, as measured by ELISA.

Authors:  B J Law; M I Marks
Journal:  J Infect Dis       Date:  1985-06       Impact factor: 5.226

Review 9.  Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy.

Authors:  C S Bryan; K L Reynolds; E R Brenner
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

10.  Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.

Authors:  E J Ziegler; J A McCutchan; J Fierer; M P Glauser; J C Sadoff; H Douglas; A I Braude
Journal:  N Engl J Med       Date:  1982-11-11       Impact factor: 91.245

View more
  5 in total

1.  Serum immunoglobulins in acute lymphoblastic leukaemia.

Authors:  M M Reid
Journal:  Arch Dis Child       Date:  1990-12       Impact factor: 3.791

2.  Endotoxin immunity and the development of the systemic inflammatory response syndrome in critically ill children.

Authors:  R C M Stephens; K Fidler; P Wilson; G R Barclay; M G Mythen; G L J Dixon; M W Turner; N J Klein; M J Peters
Journal:  Intensive Care Med       Date:  2006-02-01       Impact factor: 17.440

3.  Cross-reactivity of monoclonal antibodies and sera directed against lipid A and lipopolysaccharides.

Authors:  H M Kuhn
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

4.  Late immune recovery in children treated for malignant diseases.

Authors:  Gabor T Kovacs; Olga Barany; Barbara Schlick; Monika Csoka; Judit Gado; Andrea Ponyi; Judit Müller; Julia Nemeth; Peter Hauser; Daniel J Erdelyi
Journal:  Pathol Oncol Res       Date:  2008-06-25       Impact factor: 3.201

5.  Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins.

Authors:  G Behre; I Schedel; B Nentwig; B Wörmann; M Essink; W Hiddemann
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.